Vanguard Group Inc. Decreases Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Vanguard Group Inc. decreased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 1.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,395,583 shares of the biopharmaceutical company’s stock after selling 60,504 shares during the quarter. Vanguard Group Inc. owned about 0.06% of Vanda Pharmaceuticals worth $13,956,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 4,387 shares during the last quarter. SageView Advisory Group LLC acquired a new stake in shares of Vanda Pharmaceuticals in the 1st quarter worth $34,000. Raymond James & Associates acquired a new stake in shares of Vanda Pharmaceuticals in the 4th quarter worth $42,000. Mackenzie Financial Corp purchased a new position in shares of Vanda Pharmaceuticals during the 4th quarter worth $46,000. Finally, Empowered Funds LLC boosted its position in shares of Vanda Pharmaceuticals by 8.2% during the 1st quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company’s stock valued at $827,000 after acquiring an additional 15,215 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research report on Tuesday. They set a “hold” rating for the company. Cantor Fitzgerald raised their price target on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Trading Down 0.4 %

Shares of VNDA opened at $5.11 on Wednesday. The company’s 50-day moving average price is $5.80 and its 200 day moving average price is $4.92. Vanda Pharmaceuticals Inc. has a 12-month low of $3.30 and a 12-month high of $6.75. The firm has a market cap of $297.86 million, a P/E ratio of -63.88 and a beta of 0.75.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.